Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies

IMPORTANCE: Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk increase is not well established in real-world...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:JAMA Neurol
Huvudupphovsmän: Luna, Gustavo, Alping, Peter, Burman, Joachim, Fink, Katharina, Fogdell-Hahn, Anna, Gunnarsson, Martin, Hillert, Jan, Langer-Gould, Annette, Lycke, Jan, Nilsson, Petra, Salzer, Jonatan, Svenningsson, Anders, Vrethem, Magnus, Olsson, Tomas, Piehl, Fredrik, Frisell, Thomas
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Medical Association 2019
Ämnen:
Original Investigation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784753/
https://ncbi.nlm.nih.gov/pubmed/31589278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2019.3365
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk